武田藥品

出自 MBA智库百科(https://wiki.mbalib.com/)

本條目包含過多不是中文的內容，歡迎協助翻譯。 若已有相當內容譯為中文，可逕自去除本模板。

　　武田藥品工業網站網址：http://www.takeda.co.jp/ 日文 全球網站：http://www.takeda.com/worldwide/ 英文

　　武田藥品有限公司（Takeda Pharmaceutical Company Limited，TYO：4502）成立於1925年1月29日，總部位於大阪，註冊資本為635億日元。根據2012年IMS的銷售額數據，武田藥品是日本最大的製藥公司，是全球製藥和消費者保健行業居於領先地位的跨國集團。公司秉承“為世界人民的健康和健康的生活做貢獻”的經營理念，致力於藥品的研究開發，公司在日本、美國和歐洲先後建立研發中心，營銷網路遍及歐洲、美洲、亞洲的主要國家，藥品銷售到全球90多個國家地區。

　　公司的主要產品有：

• 蘭索拉唑(lansooprazole，Prevacid)
• 亮丙瑞林(leuprorelin，Leuplin)
• 伏格列波糖 (voglibose，Basen)
• 頭孢替安(cefotiam，Pansporin)
• 口服抗糖尿病藥吡格拉酮 (pioglitaznone，Actos)
• 血管緊張素Ⅱ拮抗劑坎伐沙坦(candesartan)

　　天津武田藥品有限公司

　　天津武田藥品有限公司是日本武田藥品株式會社與原天津力生製藥廠，現天津力生製藥有限公司合資興建的現代化製藥企業。公司成立於1996年8月28日，總投資額2620萬美元，註冊資本1920萬美元，其中外方占75%，中方占25%。在全國設有10個辦事機構，營銷網路覆蓋中國主要市場。

　　臺灣武田藥品工業公司

　　臺灣武田藥品工業公司創立於民國51年，是武田藥品重要的海外分支機構之一。自公司創立以來，臺灣武田就秉持著『為貢獻人類的健康及高品質生活』之經營理念，持續引進優越的新處方藥品，積極提升了臺灣社會人群之福祉。除了行銷臺灣地區以外，臺灣武田也於民國90年成立香港分公司，將成為港澳地區的優良藥品公司。

　　Takeda Pharmaceutical Company Limited (TYO: 4502) is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company, employing over 19,000 employees and achieving $15.7 billion USD in revenue during the 2008 fiscal year. The company is focused on metabolic disorders, gastroenterology, central nervous system disorders, inflammation, as well as oncology through its independent subsidiary

　　Takeda Pharmaceuticals was first founded on June 12, 1781 and was incorporated on January 29, 1925.

　　In 1977, Takeda first entered the U.S. pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals. Through TAP Pharmaceuticals, Takeda and Abbott launch blockbusters Lupron (leuprolide) in 1985 and Prevacid (lansoprazole) in 1995.

　　One of the firm's mainstay drugs is Actos, a compound in the thiazolidinedione class of drugs used in the treatment of Type 2 Diabetes. Launched in 1999 by Takeda's newly formed American subsidiary at the time distinct from TAP, Takeda Pharmaceuticals North America, and formerly co-marketed with Eli Lilly, Actos has become the best-selling diabetes drug in the world with $4 billion USD in sales during the 2008 fiscal year.

　　In February 2005, Takeda announced its acquisition of San Diego, CA-based Syrrx, a company specializing in high-throughput X-ray crystallography, for $270 million.

　　In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market.

　　In March 2008, Takeda and Abbott Laboratories announced plans to conclude their highly successful 30-year old joint venture TAP Pharmaceuticals that had over $3 billion in sales in its final year. The split resulted in Abbott acquiring U.S. rights to Lupron and the drug's support staff. On the other hand, Takeda received rights to Prevacid and TAP's pipeline candidates. The move also increased Takeda's headcount by 3,000 employees.

　　In April 2008, Takeda announced that it was acquiring Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for $8.8 billion. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas.

　　In May 2008, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.

　　Some of the key products that Takeda produces or markets on behalf of partners include:

• Actos (pioglitazone) - Type 2 Diabetes
• Amitiza (lubiprostone) - Chronic idiopathic constipation
• Basen (voglibose) - Type 2 Diabetes
• Benet (risedronic acid) - Osteoporosis (Japan)
• Blopress (candesartan) - Hypertension
• Enbrel (etanercept) - Inflammatory diseases (Japan)
• Kapidex (dexlansoprazole) - Gastroesophageal reflux disease
• Lupron/Leuplin (leuprorelin) - GnRH agonist for prostate cancer and endometriosis
• Prevacid/Takepron (lansoprazole) - Gastroesophageal reflux disease
• Rozerem (ramelteon) - Insomnia
• Uloric (febuxostat) - Gout
• Velcade (bortezomib) - Multiple myeloma & mantle cell lymphoma (Millennium Pharmaceuticals)